EN DE
Watch Creo Medical Group PLC for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Creo Medical Group PLC (CREO) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Creo Medical Group PLC stock £0.20, price £0.11, upside +88.2%, quality 58 out of 100. Rating: strongly undervalued. Calculated from audited financials with 9 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB · ISIN GB00BZ1BLL44

CM Creo Medical Group PLC logo Thin data Nov 7, 2026

Creo Medical Group PLC

CREO · LSE
Undervalued, but sideways

The stock costs 47% less than our calculation considers fair.

Fair value £0.2000 · Strongly undervalued
Highly profitable · 88.3% net margin (FY2025)
Low debt
Ranks above peers (7/9)
Revenue last quarter +46% vs. a year ago.
Quality 58/100
Moderate moat 49/100 · thin data
Weak Growth (revenue 5y −8.6 %/yr in GBP)
Negative free cash flow
Thin data
Watch Creo Medical Group PLC for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£1.91 £0.0955 Fair Value £0.2000 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range £0.0955 – £1.91 · fair‑value band £0.1400 – £0.2600 · the £0.1063 price screens below the £0.2000 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Creo Medical Group in your weekly email

Every Wednesday you see whether Creo Medical Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom.

Show moreShow less

It develps CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope.

The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; and SpydrBlade Flex, a multi-modal endoscopic scissor-type device.

In addition, it provides endotherapy accessories comprising injection needles, haemostatic clips, snares, and forceps, as well as other products for gastroenterology, pulmonology, and urology. Further, the company offers products for diagnostic, therapeutic, and hygiene purposes.

Creo Medical Group PLC was founded in 2003 and is headquartered in Chepstow, the United Kingdom.

Stock analysis

Creo Medical Group PLC (CREO) currently trades at £0.1063, while our model-based Fair Value estimate is £0.2000, implying the stock looks roughly 47% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of £0.2600 per share, and 6 of the 9 models we run sit above the £0.1063 price.

Bear case: the Asset-Based group reads lowest at £0.0300, and 3 of the 9 models stay below the price. Data coverage for this calculation is low.

Scenario range: £0.1400 (bear) to £0.2600 (bull), the price of £0.1063 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Creo Medical Group PLC reported revenue of £6.0M in FY2025 versus £25.2M in FY2021, a compound −30.1%/yr. Reported net income was £5.3M in FY2025.

Key figures

Market cap £47.7M Micro · P/S ratio 7.22 · EPS (TTM) £−0.1000 · Net margin 88.3% · Return on equity −29.2% · Return on assets (EBIT) −36.5% (5-year average) · Operating margin −228% · Revenue (TTM) £7.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).

What moves the price

The share trades about 40% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 88%, CREO screens cheaper than that median.

Fair Value models

Bear £0.1400 Fair Value £0.2000 Bull £0.2600
Price £0.1063 · Upside +88.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income £0.0900 £0.0900 £0.1100 71
Growth-Adj P/E £0.1400 £0.2000 £0.2600 67
Graham-Dodd £0.0800 £0.3000 £0.4100 64
All 9 models by family
Earnings-Based
Graham-Dodd £0.0800 £0.3000 £0.4100 64
Lynch FV £0.0700 £0.1100 £0.1400 61
PEG = 1.0 £0.0700 £0.1100 £0.1400 57
Multiples
P/E Multiple £0.1900 £0.2600 £0.3200 63
P/S Multiple £0.0400 £0.0500 £0.0600 58
P/B Multiple £0.3700 £0.4900 £0.6100 55
Asset-Based
NCAV (Graham) £0.0200 £0.0300 £0.0400 54
Economic Profit
Residual Income £0.0900 £0.0900 £0.1100 71
Growth Earnings
Growth-Adj P/E £0.1400 £0.2000 £0.2600 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 58/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 42
How much profit the company makes from its sales and capital
Quality Growth 74
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 41
How calm the share price moves, does not count
Price momentum 26
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 20
Distance to the 52-week high, does not count
New shares 33
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 9/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+50.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−39.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.6%
Start year 2020 (pandemic)
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−248.1% (2020) → −345.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Watch CREO, get fair value alerts →

Compare Creo Medical Group PLC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 7/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 58 · Above median
Fair Value upside +88.2% · Top 25%
Profitability
Return on assets 9.0% · Top 25%
Net margin (12 months) 88.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 45.5% · Top 25%
Balance sheet
Debt / equity 0.04× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.95× · Cheapest 25%
P/S (12 months) 6.82× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 6
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 17
HEALTH (low debt)98 · sector 98
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs CREO
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs CREO
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs CREO
DexCom, Inc DXCM $79.41 $87.35 +10% vs CREO
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs CREO
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs CREO
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs CREO
Abbott Laboratories, ABT $109.93 $75.28 −32% vs CREO
Medtronic plc MDT $101.80 $65.61 −36% vs CREO
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs CREO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Creo Medical Group PLC: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Creo Medical Group PLC Fair Value". https://www.fairvalue-calculator.com/stock/CREO

Frequently asked questions

Is Creo Medical Group PLC (CREO) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of £0.2000 versus a price of £0.1063, about +88% upside (undervalued).
What is the fair value of CREO?
Our model-based fair value for Creo Medical Group PLC is £0.2000 (as of Nov 7, 2026), built from audited fundamentals. The current price: £0.1063.
What is the quality score of CREO?
Creo Medical Group PLC has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Creo Medical Group PLC (CREO)?
Our model-based price target is the fair value of £0.2000 (as of Nov 7, 2026) from 9 valuation models. Cautious scenario £0.1400, optimistic scenario £0.2600. It is a calculation from audited fundamentals, not an analyst target.
What is the Creo Medical Group PLC stock forecast for 2026?
Our models put fair value at £0.2000, about +88% upside versus a price of £0.1063 (undervalued). Cautious scenario £0.1400, optimistic scenario £0.2600. The calculation is refreshed regularly with new filings.
What is the revenue of Creo Medical Group PLC (CREO)?
Creo Medical Group PLC reported trailing-twelve-month revenue of about £7.0M (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Creo Medical Group PLC (CREO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Creo Medical Group PLC it is £0.2000 per share (as of Nov 7, 2026), against a price of £0.1063. It is the blended result of 9 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Creo Medical Group PLC stock overvalued or undervalued in 2026?
As of Nov 7, 2026, CREO trades below its calculated fair value: price £0.1063, fair value £0.2000, a gap of about +88% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CREO?
No. The price is what the market pays today (£0.1063); the fair value is what the company's own numbers justify (£0.2000). For Creo Medical Group PLC the two are £0.0938 per share apart. That gap is exactly why we show both numbers side by side.
How much is Creo Medical Group PLC worth?
The market values Creo Medical Group PLC at about £47.7M (market capitalisation, as of Nov 7, 2026). Per share that is £0.1063; our models calculate a fair value of £0.2000 per share.
What do the bullish and bearish scenarios say about CREO?
Our models span a range for Creo Medical Group PLC: cautious scenario £0.1400, base £0.2000, optimistic £0.2600 per share (as of Nov 7, 2026, price £0.1063). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Creo Medical Group PLC (CREO)?
Balance-sheet figures for Creo Medical Group PLC (as of Nov 7, 2026): return on equity −29.2%, debt of 0.04 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is CREO from its 52-week high?
Creo Medical Group PLC trades at £0.1063, about 40% below its 52-week high of £0.1775 and 10% above the low of £0.0965 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of £0.2000 is for.
Which stocks are comparable to Creo Medical Group PLC?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Creo Medical Group PLC stock attractive at the current price?
The data as of Nov 7, 2026: price £0.1063, calculated fair value £0.2000 (+88%), Quality Score 58/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CREO calculated?
We run Creo Medical Group PLC through 9 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of £0.2000 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Creo Medical Group PLC currently trades 47% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Creo Medical Group PLC (CREO)?
The closing price on Nov 6, 2026 was £0.1063. Our model-based fair value is £0.2000, about +88% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Creo Medical Group PLC right now?
The price is below even our cautious bear case (£0.1400). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (£0.1400 to £0.2600) leaves room in how you read the outcome.

Key figures of Creo Medical Group PLC

How large is the market capitalisation of Creo Medical Group PLC (CREO)?
The market capitalisation of Creo Medical Group PLC is £47.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Creo Medical Group PLC (CREO)?
The price-to-sales ratio of Creo Medical Group PLC is 7.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Creo Medical Group PLC (CREO)?
Earnings per share at Creo Medical Group PLC are £−0.1000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Creo Medical Group PLC (CREO)?
The net margin of Creo Medical Group PLC is 88.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Creo Medical Group PLC (CREO)?
The return on equity (ROE) of Creo Medical Group PLC is −29.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Creo Medical Group PLC (CREO)?
On an EBIT basis the return on assets of Creo Medical Group PLC is −36.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Creo Medical Group PLC (CREO)?
The operating margin of Creo Medical Group PLC is −228% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Creo Medical Group PLC (CREO)?
Revenue at Creo Medical Group PLC is growing +45.5% versus a year earlier (3y avg −39.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Creo Medical Group PLC (CREO) generate?
The free cash flow of Creo Medical Group PLC is −£18.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Creo Medical Group PLC (CREO) hold?
Creo Medical Group PLC holds more cash than debt, £8.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Creo Medical Group PLC in the live analysis

One click puts Creo Medical Group PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.